Literature DB >> 6220848

Complement-mediated inhibition of immune precipitation in patients with immune complex diseases.

J K Naama, W S Mitchell, A Zoma, J Veitch, K Whaley.   

Abstract

The ability of human sera to prevent the precipitation of antigen-antibody complexes has been investigated. The early complement components including C3 are required for optimal prevention of immune precipitation, whereas the later components are not required. The sera of 36 of 75 patients with seropositive rheumatoid arthritis (RA), 14 of 32 with SLE and four of 17 with glomerulonephritis exhibited reduced capacities to prevent immune precipitation. In contrast sera from patients with seronegative RA, ankylosing spondylitis, psoriatic arthritis or degenerative joint disease were normal in this respect. In SLE and GN sera hypocomplementaemia was frequently associated but not always with failure to prevent immune precipitation, whereas only a small proportion of the patients with seropositive RA and reduced capacity to retain complexes in a soluble form were hypocomplementaemic. Thus the failure of sera to prevent the precipitation of antigen-antibody complexes is not always associated with hypocomplementaemia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6220848      PMCID: PMC1536892     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Precise standardization of reagents for complement fixation.

Authors:  J F KENT; E H FIFE
Journal:  Am J Trop Med Hyg       Date:  1963-01       Impact factor: 2.345

2.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

4.  Modulation of C2 biosynthesis by antigen-antibody complexes.

Authors:  A R McPhaden; K Whaley
Journal:  J Clin Lab Immunol       Date:  1982-01

5.  IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy.

Authors:  D G Scott; P A Bacon; C Allen; C J Elson; T Wallington
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

6.  Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.

Authors:  J A Schifferli; P Woo; D K Peters
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

7.  Inhibition of immune precipitation by complement.

Authors:  J A Schifferli; S R Bartolotti; D K Peters
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

8.  Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes.

Authors:  M Takahashi; B F Tack; V Nussenzweig
Journal:  J Exp Med       Date:  1977-01-01       Impact factor: 14.307

9.  Studies on the mechanism of solubilization of immune precipitates by serum.

Authors:  J Czop; V Nussenzweig
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

  9 in total
  22 in total

1.  Molecular characterisation of C4 null alleles found in Felty's syndrome.

Authors:  M C Hillarby; T Strachan; D M Grennan
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

2.  Familial properdin deficiency associated with chronic discoid lupus erythematosus.

Authors:  E R Holme; J Veitch; A Johnston; G Hauptmann; B Uring-Lambert; M Seywright; V Docherty; W N Morley; K Whaley
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

3.  Prevention of immune precipitation by purified components of the alternative pathway.

Authors:  J K Naama; E Holme; E Hamilton; K Whaley
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

4.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

5.  An inhibitor of complement-mediated prevention of immune precipitation in rheumatoid arthritis--relationship to disease activity and systemic manifestations.

Authors:  W S Mitchell; J Veitch; J Hunter; A Zoma; H Capell; K Whaley
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

6.  Purification of a plasma protein that inhibits complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; K Whaley
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

7.  Inhibition of C1q binding to antigen-antibody complexes by a factor in rheumatoid arthritis serum.

Authors:  I P Niven; K Whaley
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

8.  Complement mediated inhibition of immune precipitation in rheumatoid arthritis: studies on interaction of heat aggregated IgG with IgM rheumatoid factor.

Authors:  M M O'Sullivan; N Amos; B D Williams
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

9.  The role of C1, C1-inactivator and C4 in modulating immune precipitation.

Authors:  J A Schifferli; G Steiger; M Schapira
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

10.  Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate.

Authors:  D Lewis; H A Capell
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.